ImmusanT Raises $12M in Series B Financing
ImmusanT Inc., a Cambridge, Mass.-based developer of an immunotherapy for Celiac Disease, raised $12m in Series B financing. Vatera Healthcare Partners LLC made the investment. Led by Leslie Williams, president and CEO, ImmusanT develops Nexvax2, a disease-modifying immunotherapy designed to enable patients with celiac disease to have a diet containing gluten by tolerizing, or reprogramming, […]